Dermata Therapeutics Statistics
Total Valuation
DRMA has a market cap or net worth of $4.63 million. The enterprise value is $212,700.
| Market Cap | 4.63M |
| Enterprise Value | 212,700 |
Important Dates
The next estimated earnings date is Friday, November 13, 2026, after market close.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DRMA has 4.02 million shares outstanding. The number of shares has increased by 391.14% in one year.
| Current Share Class | 4.02M |
| Shares Outstanding | 4.02M |
| Shares Change (YoY) | +391.14% |
| Shares Change (QoQ) | +4.23% |
| Owned by Insiders (%) | 27.75% |
| Owned by Institutions (%) | 6.26% |
| Float | 2.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 13.21 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.81
| Current Ratio | 2.81 |
| Quick Ratio | 2.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -183.89% and return on invested capital (ROIC) is -118.12%.
| Return on Equity (ROE) | -183.89% |
| Return on Assets (ROA) | -89.88% |
| Return on Invested Capital (ROIC) | -118.12% |
| Return on Capital Employed (ROCE) | -246.61% |
| Weighted Average Cost of Capital (WACC) | 8.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$929,850 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.89% in the last 52 weeks. The beta is 0.69, so DRMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -77.89% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.45 |
| Relative Strength Index (RSI) | 39.83 |
| Average Volume (20 Days) | 29,758 |
Short Selling Information
The latest short interest is 120,024, so 2.98% of the outstanding shares have been sold short.
| Short Interest | 120,024 |
| Short Previous Month | 167,251 |
| Short % of Shares Out | 2.98% |
| Short % of Float | 4.14% |
| Short Ratio (days to cover) | 1.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.60M |
| Pretax Income | -8.37M |
| Net Income | -8.37M |
| EBITDA | n/a |
| EBIT | -8.60M |
| Earnings Per Share (EPS) | -$3.33 |
Balance Sheet
The company has $4.41 million in cash and no debt, with a net cash position of $4.41 million or $1.10 per share.
| Cash & Cash Equivalents | 4.41M |
| Total Debt | n/a |
| Net Cash | 4.41M |
| Net Cash Per Share | $1.10 |
| Equity (Book Value) | 3.49M |
| Book Value Per Share | 0.87 |
| Working Capital | 3.32M |
Cash Flow
In the last 12 months, operating cash flow was -$8.03 million and capital expenditures -$110,667, giving a free cash flow of -$8.14 million.
| Operating Cash Flow | -8.03M |
| Capital Expenditures | -110,667 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -8.14M |
| FCF Per Share | -$2.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -391.14% |
| Shareholder Yield | -391.14% |
| Earnings Yield | -181.00% |
| FCF Yield | -176.17% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 1, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Aug 1, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |